A study on osteogenesis promoted by PTH (1-34) and polylysine coating on the surface of implant

WANG Xingxing; LUO Xiaolong; WU Gang; HAN Xu; GUO Xiaojing; and WANG Dalin

PDF(1057 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2016, Vol. 27 ›› Issue (8) : 814-818.

ORIGINAL ARTICLES

A study on osteogenesis promoted by PTH (1-34) and polylysine coating on the surface of implant

WANG Xingxing¹, LUO Xiaolong¹, WU Gang¹, HAN Xu¹, GUO Xiaojing², and WANG Dalin¹

Author information +

History +

Abstract

Objective To promote osteogenesis, parathyroid hormone which can promote bone formation was used to process surface of implant material.Methods Parathyroid hormone PTH (1-34) and polylysine were coated to the surface of the implant material through layer by layer self-assemble technique. ELISA was used to explore the in vitro pharmacokinetics regularity of the coating. The mouse embryos osteogenesis precursor cells MC3T3 E1 were seeded on the coated implant material surface. MTT, alkaline phosphatase semi-quantitative and PCR Methods were used to detect the in vitro influence of osteoblast biology behavior.Results PLL - PTH (1-34) polyelectrolyte multilayer membrane coating made by layer by layer self-assemble technique showed significant release process in the initial phase, then the release leveled off, and PTH (1-34) could be detected until 14 d. MTT: OD value of group C (1.738±0.026) on the 5 d elevated compared with 1 d (1.663±0.045) (P=0.0219). Alkaline phosphatase semi-quantitative: activity of alkaline phosphatase in group C (3.377±0.336) U/gprot was higher than in group A (2.537±0.083) U/gprot, B (2.843±0.060) U/gprot and D(2.063±0.061) U/gprot; the difference was statistically significant (P<0.05). PCR: expression level of ALP in four groups were highest on 7 d, and in group C was higher than in groups A, B and D (the difference was statistically significant, P<0.05); expression level of OCN in four groups were highest on 14 d, and in group C was higher than in groups A, B and D (the difference was statistically significant, P<0.05).Conclusions PLL - PTH (1-34) polyelectrolyte multilayer membrane can be made on implant material surface through layer by layer self-assemble technique. PTH (1-34) can release for a long time (14 d) by this technique, so as to promote proliferation and differentiation of the osteoblasts seeded on the surface.

Key words

PTH(1-34) / polylysine / layer by layer self-assemble technique / implant

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Xingxing, LUO Xiaolong, WU Gang, HAN Xu, GUO Xiaojing, and WANG Dalin. A study on osteogenesis promoted by PTH (1-34) and polylysine coating on the surface of implant[J]. Medical Journal of the Chinese People Armed Police Forces. 2016, 27(8): 814-818

References

[1] Branemark P I. Osseointegration and its experimental background [J]. J Prosthet Dent,1983,50(3):399-410.
[2] Qin L, Raggatt L J, Partridge N C. Parathyroid hormone: a double-edged sword for bone metabolism [J]. Trends Endocrinol Metab, 2004,15(2):60-65.
[3] Farra R, Sheppard N F, Mccabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip [J]. Sci Transl Med,2012,4(122):122ra121.
[4] Nardi A, Ventura L, Cozzi L, et al. The bone anabolic therapy [J]. Aging Clin Exp Res, 2013, 25 (Suppl 1):S121-S124.
[5] Hadji P, Zanchetta J R, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures [J]. Osteoporos Int, 2012,23(8):2141-2150.
[6] Mcneilly T, Mcnally C, Finch M, et al. Recombinant PTH: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis [J]. Ulster Med J, 2013,82(2):89-93.
[7] Gabet Y, Muller R, Levy J, et al. Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis [J]. Bone, 2006, 39(2): 276-282.
[8] Shirota T, Tashiro M, Ohno K, et al. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats [J]. J Oral Maxillofac Surg, 2003, 61(4): 471-480.
[9] Almagro M I, Roman-Blas J A, Bellido M, et al. Pth[1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis [J]. Clin Oral Implants Res, 2013, 24(9): 1027-1034.
[10] Ohkawa Y, Tokunaga K, Endo N. Intermittent administration of human parathyroid hormone (1-34) increases new bone formation on the interface of hydroxyapatitecoated titanium rods implanted into ovariectomized rat femora [J]. J Orthop Sci, 2008,13(6):533-542.
[11] Li Y F, Li X D, Bao C Y, et al. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface [J]. Osteoporos Int, 2013, 24(3): 1063-1071.
[12] Onyia J E, Helvering L M, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (pth) in rat bone: an analysis by DNA microarray [J]. J Cell Biochem, 2005, 95(2): 403-418.
[13] Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis [J]. J Biol Chem, 2007, 282(45): 33086-33097.
[14] Jilka R L, O'brien C A, Ali A A, et al. Intermittent pth stimulates periosteal bone formation by actions on post-mitotic preosteoblasts [J]. Bone, 2009, 44(2): 275-286.
[15] Augustine M, Horwitz M J. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis [J]. Curr Osteoporos Rep, 2013, 11(4): 400-406.
[16] Tam C S, Heersche J N, Murray T M, et al. Parathyroid hormone stimulates the bone apposition rateindependently of its resorptive action: Differential effects of intermittent and continuous administration [J]. Endocrinology,1982,110(2):506-512.
[17] Datta N S, Abou-Samra A B. Pth and pthrp signaling in osteoblasts [J]. Cell Signal,2009,21(8):1245-1254.
[18] Ishizuya T. Effects of parathyroid hormone on bone metabolism : differences between intermittent and continuous treatment [J]. Clin Calcium, 2012, 22(3): 357-363.
[19] Jilka R L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH [J]. Bone, 2007, 40(6): 1434-1446.
[20] Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate [J]. N Engl J Med, 2005, 353(6): 566-575.
[21] Hodsman A B, Bauer D C, Dempster D W, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use [J]. Endocr Rev, 2005, 26(5):688-703.
[22] 刘明,潘薇,陈德才.甲状旁腺激素治疗骨质疏松症的研究进展 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2012,5(2):151-156.
[23] Valderrama P, Jung R E, Thoma D S, et al. Evaluation of parathyroid hormone bound to a synthetic matrix for guided bone regeneration around dental implants: a histomorphometric study in dogs [J]. J Periodontol, 2010, 81(5): 737-747.
[24] Yu X, Wang L, Jiang X, et al. Biomimetic cap coating incorporated with parathyroid hormone improves the osseointegration of titanium implant [J]. J Mater Sci Mater Med, 2012, 23(9): 2177-2186.